Ribupatide Phase 3 HRS9531 302 reports positive topline results in type 2 diabetes
KEY STEPHengrui reported positive topline results from the HRS9531 302 Phase 3 trial of ribupatide injection in treatment naive adults with type 2 diabetes in China. Both doses produced significant HbA1c reductions, and the company said it plans to submit a new drug application for glycemic control.
Roadmap reference